
    
      -  Investigational groups: 3, each receive one of 3 lots of DTaP-IPV vaccine.

        -  Control: US-licensed DTaP (Infanrix) + US-licensed IPV (IPOL) vaccines administered in
           separate injections.

        -  Two study visits one month apart for a subset of subjects (Safety and Immunogenicity
           subset) with a blood draw at each visit. All other subjects will have one visit.

        -  A telephone contact 4-6 days after vaccination for all subjects, a telephone contact
           31-38 days after vaccination for the Safety only subset and a telephone contact for all
           subjects during the extended safety follow-up phase (5 months following the active
           phase).
    
  